STOCK MARKET BSE NSE

Cipla all set to launch Favipiravir drug for treatment of COVID patients: CSIR

An off-patent anti-viral drug, Favipiravir, originally discovered by Fuji Pharma in Japan, has shown promise in clinical trials for treatment of COVID-19 patients, especially in mild, moderate cases

Published: 23rd July 2020 09:32 PM  |   Last Updated: 23rd July 2020 09:32 PM   |  A+A-

Glenmark Pharmaceuticals has initiated phase three of clinical trials in India on antiviral tablet Favipiravir

Biophore India Pharmaceuticals announced completion of the validation of Favipiravir and the decision to scale up its production. (File photo| ANI)

By PTI

NEW DELHI: Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.

An off-patent anti-viral drug, Favipiravir, originally discovered by Fuji Pharma in Japan, has shown promise in clinical trials for the treatment of COVID-19 patients, especially in mild and moderate cases.

CSIR-Indian Institute of Chemical Technology (CSIR-IICT) developed a cost-effective process using locally available chemicals to synthesize this Active Pharmaceutical Ingredient (API) and transferred the technology to Cipla.

"Cipla has scaled up the process in their manufacturing facility and approached DCGI (Drug Controller General of India) for permission to launch the product in India. Given that DCGI has given restricted emergency use for Favipiravir in the country, Cipla is now all set to launch the product to help patients suffering from COVID-19," the statement said.

Commenting on the development, Director of CSIR-IICR S Chandrashekhar said the technology is very efficient and makes it affordable and allows Cipla to make large quantities of the product within a short span of time.

CSIR Director General Shekhar C Mande observed that they are working with the industry in developing quick solutions and products for mitigation of COVID-19 and this partnership with Cipla is an example of how CSIR is committed to bringing repurposed drugs soon.

Stay up to date on all the latest Nation news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp